June, 2024
June 2024
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Zhi Ven Fong: Our study as June’s Feature article in Annals of Surgery
Jun 19, 2024, 14:22

Zhi Ven Fong: Our study as June’s Feature article in Annals of Surgery

Zhi Ven Fong, Pancreas and Liver surgeon at Mayo Clinic, shared on X: 

“Grateful to Annals of Surgery for publishing our study as June’s Feature article!

Ever come across that stat sig (p<0.05), but with small diff btw study arms for it to be clinically meaningful? How pervasive is this?

We’ve got you covered in this thread: 

Zhi Ven Fong

With recent advancements in the use of large data research and multicenter RCTs, it is important for us to distinguish clinical from statistical sig because even slightest diff in% can yield p<0.05 w large sample sizes.

Implications on trial design and drug approval are immense. Poster child below.

Zhi Ven Fong

We tried to quantify how often papers would report stat sig without discerning clinical meaningfulness of between-group diff and if treatment change was recommended.

We queried 1 year’s worth of papers from Annals of Surgery, JAMA, Journal of Clinical Oncology, Journal of Surgical Research, and Journal of the American College of Surgeons (JACS) to get a good mix.

Zhi Ven Fong

307 studies were reviewed. 54.7% had statistically significant outcomes. Only 8.5% discussed the clinical significance of between-group differences.

There were 7 (2.3%) studies where change in treatment was recommended, of which 5 did so without defining clinical significance.

Zhi Ven Fong

How does this compare to the past?
There was a study looking at the same issue and found that 19% of trials from 1975 to 1990 made an effort to determine if between-group differences were clinically meaningful.
30 years later, we’re not just no better, but fared worse at 8.5%.
Zhi Ven Fong

As expected as well, for more studies reviewed, we correlated the reviewed studies’ sample sizes (x-axis) with the magnitude of between-group differences (y-axis) in their analyses and the association was quite linear.

Simply, it was a lot easier to hit p<0.05 with large sample sizes.

Zhi Ven Fong

While this isn’t earth-shattering, intent was to reshine on an important issue.

This has implications on FDA/NICE approval of drugs and devices.

We join Dr Clavien’s call for action in his Editorial. We need to figure this out or someone else will for us!

Zhi Ven Fong

This was a team effort by Harvard Medical School student, Ajami Gikandi, who’s applying for residency this year. Stud, rock star, keep an eye out for him!

And significant contributions from Julie Hallet, Bas Groot Koerkamp, Marc Besselink, Clancy J. Clark, Dana Gelb Safran, Raja Narayan, Harvey Mamon, and Joel Weissman.”

Source: Zhi Ven Fong/X